Solving the Capacity Crisis for Viral Vector Manufacturing

Solving the Capacity Crisis for Viral Vector Manufacturing

Viral vectors for gene therapy have shown tremendous clinical promise which has spurred a huge increase in demand for manufacturing space, resulting in a capacity crisis. This is currently delaying the commercialization of these gene therapies for which time to market is critical.

Integrated solutions for viral vectors designed within modular cleanroom facilities streamline manufacturing and reduce time to market. Pall Biotech and G-CON manufacturing have partnered to design and deploy an integrated manufacturing solution to address the current capacity constraints for viral vector manufacturing.

Participants will learn:

  1. The manufacturing challenges facing the viral vector industry
  2. The advantages of an integrated manufacturing solution
  3. How to develop and deploy a new manufacturing facility in 10 months within a modular cleanroom

 

 

 

Moderator

 

 

Clive Glover

 

Director, Cell & Gene Therapy
Pall Biotech

Biography

 

 

 

Presenters

 

 

 

Jeremy Rautenbach

 

Global Product Manager, Integrated Solutions
Pall Biotech

Joseph Rininger

 

Director, Cell & Gene Therapy
Latham BioPharm Group

Peter Makowensky

 

Director, Sales Engineering

G-CON Manufacturing

Maximize Speed to Market Flexibility of Single-Use for Gene Therapy Manufacturing

Listen to Podcast Today

더 Biotech Webinars
Our webinars keep you informed on the latest products and technologies, current industry topics, the latest trends and a range of innovations and solutions to help continuously improve your processes.
October 2021
Integrity Assurance for Single-Use Systems: An End-User’s Perspective

Biotech | Pall Corporation 웨비나 시리즈

Integrity Assurance for Single-Use Systems An End-User’s Perspective

 

What should you consider when building an integrity control strategy for your single-use systems (SUS)? How do you overcome application challenges?

 

Join leading industry experts Charlotte Masy of GSK and Patrick Evrard from Pall Corporation to gain insights and answers in this webinar from BioPharma Asia on integrity Assurance for Single-Use Systems, an End-User’s Perspective. They will present several case studies to show how integrity concerns can be practically addressed for cGMP manufacturing applications and the results observed a few years on. 

 

Attendees will learn about:

 

  • The latest regulatory requirements for integrity assurance of SUS
  • The different technologies available to control integrity of SUS
  • Key parameters that affect integrity measurements

 

Register now for this webinar from industry experts on October 6.

 

등록